Literature DB >> 8050175

Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection.

A Carr1, E Vasak, V Munro, R Penny, D A Cooper.   

Abstract

The pathogenesis of drug hypersensitivity in patients with HIV infection is unknown. To study further the nature of hypersensitivity, the histopathological features of morbilliform drug hypersensitivity reactions were examined in a group of HIV-infected patients. Skin sections from 23 HIV-infected subjects with morbilliform drug hypersensitivity reactions were examined by light microscopy, direct immunofluorescence and immunohistochemistry, to determine the nature of the inflammatory infiltrate and the role of immunoglobulin, complement and cytokines. The principal light microscopic findings were spongiosis, hydropic generation of the basal layer, civatte bodies, an epidermal lymphocytic infiltrate (48%), and a perivascular dermal infiltrate of lymphocytes (87%) and macrophages (52%). Two patients had findings consistent with toxic epidermal necrolysis. Immunohistochemistry demonstrated that the lymphocytic infiltrate consisted of CD8+, HLA-DR+ T lymphocytes (some of which also stained for CD38), a marked depletion of epidermal Langerhans cells (90%), and strong cytoplasmic staining of keratinocytes for IL-6 (60%), IL-1 beta (50%), tumour necrosis factor-alpha (TNF-alpha) (45%) and to a lesser degree, interferon-gamma (IFN-gamma) (35%). Immunofluorescence did not demonstrate any significant deposition of immunoglobulin or complement. The histological findings were independent of the responsible drug, the duration of either therapy or the rash, and of peripheral blood CD4+ and CD8+ cell counts. These findings suggest that activated CD8+ lymphocytes and perhaps epidermal production of cytokines are involved in the pathogenesis of cutaneous drug hypersensitivity in HIV-infected patients. The common histological features, regardless of the causative drug, suggest a common pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8050175      PMCID: PMC1534695          DOI: 10.1111/j.1365-2249.1994.tb06078.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites.

Authors:  M J Rieder; J Uetrecht; N H Shear; M Cannon; M Miller; S P Spielberg
Journal:  Ann Intern Med       Date:  1989-02-15       Impact factor: 25.391

Review 2.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.

Authors:  A S Fauci
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

3.  Prognostic value of Langerhans cells in the epidermis of HIV patients.

Authors:  B Dréno; B Milpied; J D Bignon; J F Stalder; P Litoux
Journal:  Br J Dermatol       Date:  1988-04       Impact factor: 9.302

4.  Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study.

Authors:  F R Sattler; R Cowan; D M Nielsen; J Ruskin
Journal:  Ann Intern Med       Date:  1988-08-15       Impact factor: 25.391

5.  Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients.

Authors:  A Carr; A S Gross; J M Hoskins; R Penny; D A Cooper
Journal:  AIDS       Date:  1994-03       Impact factor: 4.177

6.  A coordinated approach to children's health in India: progress report after five years (1975-1980).

Authors: 
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

7.  Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial.

Authors:  J M Wharton; D L Coleman; C B Wofsy; J M Luce; W Blumenfeld; W K Hadley; L Ingram-Drake; P A Volberding; P C Hopewell
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

8.  Dermatologic findings associated with human immunodeficiency virus infection.

Authors:  W L Matis; A Triana; R Shapiro; L Eldred; B F Polk; A F Hood
Journal:  J Am Acad Dermatol       Date:  1987-11       Impact factor: 11.527

9.  Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.

Authors:  F M Gordin; G L Simon; C B Wofsy; J Mills
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

10.  Late development of systemic lupus erythematosus in patients with glomerular "fingerprint" deposits.

Authors:  C E Alpers; J Hopper; M J Bernstein; C G Biava
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

View more
  5 in total

Review 1.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 2.  T cells in drug allergy.

Authors:  Werner J Pichler
Journal:  Curr Allergy Asthma Rep       Date:  2002-01       Impact factor: 4.806

Review 3.  Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment.

Authors:  Philip J Peters; Michael C Thigpen; Monica E Parise; Robert D Newman
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Severe erythema multiforme-type drug eruption controlled by tumor necrosis factor-α antagonist: A case study.

Authors:  Xin Ling; Xin Shi; Lingling Chen
Journal:  Exp Ther Med       Date:  2017-10-18       Impact factor: 2.447

Review 5.  Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management.

Authors:  Evy Yunihastuti; Alvina Widhani; Teguh Harjono Karjadi
Journal:  Asia Pac Allergy       Date:  2014-01-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.